File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Kringle 1 Domain of Human Hepatocyte Growth Factor (HGFK1) Inhibits the Growth and Metastasis of Hepatocellular Carcinoma in Rats

TitleKringle 1 Domain of Human Hepatocyte Growth Factor (HGFK1) Inhibits the Growth and Metastasis of Hepatocellular Carcinoma in Rats
Authors
Issue Date2007
PublisherElsevier Inc.
Citation
American Society of Gene Therapy 10th Annual Meeting, Seattle, WA, 30 May-3 June 2007. In Molecular Therapy, 2007, v. 15 n. S1, p. S234 How to Cite?
AbstractObjective: We have previously shown that recombinant protein of kringle 1 domain of human hepatocyte growth factor (HGFK1) inhibits the proliferation of bovine aortic endothelial (BAE) cells. Here we investigate the in vivo efficacy of long term expression of HGFK1 in cancer gene therapy for hepatocellular carcinoma (HCC) using the adenoassociated virus (serotype 2) carrying the HGFK1 gene (rAAV-HGFK1). Methods: Preclinical animal studies were conducted using an established orthotopic Buffalo rat HCC model. HCC was induced by injection of 1.0×106 rat hepatoma cells, McA-RH7777, into the left lobe of the liver. Ten days after tumor cell inoculation, surgeries were performed to confirm the tumor formation. Then rAAV-HGFKl (1.2×1012 v.p.), rAAV-EGFP (1.2×1012 v.p.) or PBS were injected directly into the tumor nodule (0.2×1012 v.p.) followed by portal vein (1.0×1012 v.p.) injection. Results: We first showed that infection by rAAV-HGFKl produced significant anti-angiogenesis effect as demonstrated by reduced proliferation and microvascular tube formation of mouse microvascular endothelial cells in vitro in the cell culture system. The in vivo efficacy of rAAV-HGFK1 was then evaluated in the rat model of HCC. Results from our study demonstrated for the first time that a long term expression of HGFK1 significantly prolonged the median survival rate of the HCC bearing rats from 30 days to 49 days. More importantly rAAV-HGFK1 inhibited tumor growth and completely prevented lung and peritoneal metastasis. Conclusion: Long term expression of HGFK1 might be a novel promising treatment for HCC and other cancers.
Persistent Identifierhttp://hdl.handle.net/10722/97222
ISSN
2015 Impact Factor: 6.938
2015 SCImago Journal Rankings: 3.374

 

DC FieldValueLanguage
dc.contributor.authorShen, Zen_HK
dc.contributor.authorYang, Zen_HK
dc.contributor.authorGao, Yen_HK
dc.contributor.authorPoon, RTPen_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorHe, MLen_HK
dc.contributor.authorLi, TPen_HK
dc.contributor.authorGan, RBen_HK
dc.contributor.authorKung, HFen_HK
dc.contributor.authorLin, MCen_HK
dc.date.accessioned2010-09-25T17:00:59Z-
dc.date.available2010-09-25T17:00:59Z-
dc.date.issued2007en_HK
dc.identifier.citationAmerican Society of Gene Therapy 10th Annual Meeting, Seattle, WA, 30 May-3 June 2007. In Molecular Therapy, 2007, v. 15 n. S1, p. S234-
dc.identifier.issn1525-0016-
dc.identifier.urihttp://hdl.handle.net/10722/97222-
dc.description.abstractObjective: We have previously shown that recombinant protein of kringle 1 domain of human hepatocyte growth factor (HGFK1) inhibits the proliferation of bovine aortic endothelial (BAE) cells. Here we investigate the in vivo efficacy of long term expression of HGFK1 in cancer gene therapy for hepatocellular carcinoma (HCC) using the adenoassociated virus (serotype 2) carrying the HGFK1 gene (rAAV-HGFK1). Methods: Preclinical animal studies were conducted using an established orthotopic Buffalo rat HCC model. HCC was induced by injection of 1.0×106 rat hepatoma cells, McA-RH7777, into the left lobe of the liver. Ten days after tumor cell inoculation, surgeries were performed to confirm the tumor formation. Then rAAV-HGFKl (1.2×1012 v.p.), rAAV-EGFP (1.2×1012 v.p.) or PBS were injected directly into the tumor nodule (0.2×1012 v.p.) followed by portal vein (1.0×1012 v.p.) injection. Results: We first showed that infection by rAAV-HGFKl produced significant anti-angiogenesis effect as demonstrated by reduced proliferation and microvascular tube formation of mouse microvascular endothelial cells in vitro in the cell culture system. The in vivo efficacy of rAAV-HGFK1 was then evaluated in the rat model of HCC. Results from our study demonstrated for the first time that a long term expression of HGFK1 significantly prolonged the median survival rate of the HCC bearing rats from 30 days to 49 days. More importantly rAAV-HGFK1 inhibited tumor growth and completely prevented lung and peritoneal metastasis. Conclusion: Long term expression of HGFK1 might be a novel promising treatment for HCC and other cancers.-
dc.languageengen_HK
dc.publisherElsevier Inc.-
dc.relation.ispartofMolecular Therapyen_HK
dc.titleKringle 1 Domain of Human Hepatocyte Growth Factor (HGFK1) Inhibits the Growth and Metastasis of Hepatocellular Carcinoma in Ratsen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailYang, Z: zfyang@hkucc.hku.hken_HK
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.emailLin, MC: mcllin@HKUCC.hku.hken_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.identifier.authorityLin, MC=rp00746en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S1525-0016(16)44815-X-
dc.identifier.hkuros126376en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats